Navigation Links
Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
Date:11/11/2010

DALLAS and NEW YORK, Nov. 11, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it will be presenting a poster today at the 10th Annual Diabetes Technology Meeting, entitled, "Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin."  The poster reviews the progress made by Access scientists in developing its proprietary oral insulin formulation.  Access recently rebranded its oral drug delivery technology as CobOral™ to reflect the advances made with the technology platform.

"We are delighted to share our recent findings from our CobOral insulin research at this year's Diabetes Technology Meeting," said David Nowotnik, Senior VP of Research and Development, Access Pharmaceuticals, Inc.  He continued, "Our team has made significant advancements with our CobOral drug delivery technology, particularly in the diabetes area.  We are continuing to explore additional collaborations to further the technology's promise in providing an effective and convenient method to control glucose levels in diabetic patients, and in treating other indications."

The 10th Annual Diabetes Technology Meeting is being held at the Marriott Bethesda North in Bethesda, Maryland.  For more information, visit http://www.diabetestechnology.org/.

Last week, Access received a $245,000 grant for the Cobalamin Insulin program as one of several awards under the Qualifying Therapeutic Discovery Project (QTDP).  Access recently announced agreements with a biopharmaceutical and biotechnology company to develop oral formula
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th
2. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
3. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
4. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
5. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
6. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
7. Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases
8. The Development of Medical Foundations in the San Diego Area will Restrict Physician Access for Pharmaceutical Reps
9. Recent Patient Series Demonstrates Spirus Medicals Power Spiral Endoscope Enables Unprecedented Access to GI Tract
10. Utahs Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs
11. Pemiscot Memorial Health Systems Selects ChartAccess® Comprehensive EHR From Prognosis Health Information Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 2, 2014   ... atrial muestran agentes antitrombóticos no utilizados óptimamente para ... -- Las presentaciones de GARFIELD-AF en el ESC ... y los resultados de pacientes en riesgo de ...    Los datos de casi 12.500 ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... /PRNewswire-USNewswire/ – CoMeD – On Friday, July ... (UNEP) distributed a revised text for its comprehensive ... were gratified to see pharmaceuticals listed in "Annex C ... The Coalition for Mercury-free Drugs (CoMeD) ...
... Reportlinker.com announces that a new market ... Sustained Release Injectables: Evolving ... http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... to increase the duration of efficacy for ...
Cached Medicine Technology:Global Mercury Treaty May Include Ban on Mercury in Medicine 2Global Mercury Treaty May Include Ban on Mercury in Medicine 3Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 2Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 3
(Date:9/2/2014)... Columbia, SC (PRWEB) September 02, 2014 The ... an outreach fair and public town hall meeting for Veterans ... be available at the outreach fair to provide Veterans with ... B. McMurry. “The town hall will provide a forum where ... our VA programs.” , The outreach fair will be held ...
(Date:9/2/2014)... early-stage breast cancer in California, the percentage undergoing a ... this procedure was not associated with a lower risk ... a study in the September 3 issue of ... the removal of one breast was associated with a ... in the study. , Randomized trials have demonstrated similar ...
(Date:9/2/2014)... Medex Analytic Services is delighted to announce the ... Fla. due to their greater than forecasted growth. , ... 2014 year by distinguishing Medex in the industry,” said ... level of service and professionalism in the delivery of ... has responded.” , The location of the new ...
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Two new ... One suggests that 6-year-olds who were breast-fed have a ... to bottle-fed infants, while the other finds a similar ... upholds the "many benefits of breast-feeding in the immediate ... Lenox Hill Hospital in New York City. She was ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... An Indian who moderates an Internet forum on HIV/AIDS ... 16th International AIDS Conference here scheduled from Aug 13. ... delegates to build support for eliminating disparities in access ... a conference co-chair and director of the McGill University ...
... prowess in adding muscle to existing blackcurrants with a view ... reflect in nutritive fruit beverages. The Scottish Crop Research Institute ... manufactured in the blackcurrant bushes, so that they could look ... study costing about ?1.2m will endeavor to enhance the quality ...
... cancer cells after breast cancer surgery may play a crucial ... a new study published// in the August 1, 2006, issue ... Physics, the official journal of ASTRO, the American Society for ... 213,000 American women will learn they have breast cancer. Many ...
... pregnancy counselling Medicare item number may well breach women's ... ,Available only to women who are uncertain about whether ... identification of women who talk to their GP about ... would put on the record the fact that a ...
... Low calorie foods that are high in nutrition may be the ... fear of piling calories//. After studying the dietary details of about ... vegetables and grains were likely to consume a larger quantity of ... despite consuming a lot of food, their calorie count was much ...
... paying their price by breaking bones and spraining ankles. ... off their high-heeled sandals, causing several injuries. ... emergency unit at University Hospital of Wales, Cardiff, pointed ... ,He advised women to wear shoes with ...
Cached Medicine News:Health News:Indian to Conduct Workshop at Global AIDS Meet 2Health News:Leftover Cancer Cells May Dictate Breast Cancer Relapse 2Health News:Doctors Warn on Pregnancy Counselling 2
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: